Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2025-12-24 @ 10:57 PM
NCT ID:
NCT01779869
Eligibility Criteria:
Inclusion Criteria:
* Patients who have had a clinically ordered rest/regadenoson single-isotope SPECT-MPI study within 10 days prior to cardiac PET-MRI examination
* Reversible perfusion abnormalities on SPECT imaging in at least 2 contiguous myocardial segments
* Patients for whom standard of care coronary ICA is planned
Exclusion Criteria:
* An clinical event (ie; worsening angina pectoris or myocardial infarction) occuring after the SPECT-MPI and before the cardiac MRI examination
* Myocardial revascularization occuring after the SPECT-MPI and before the cardiac MRI examination
* Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, etc.)
* Renal insufficiency (GFR \< 60 mL/min/1.73m2)
* Allergy or other contraindication to gadolinium-based MR contrast agent
* Second or third degree atrioventricular (AV) block
* Active asthma
* Seizures
* Current hypotension (\<100/60)
* Current hypertension (\>160/90)
* Pregnancy
* Breast feeding
* Use of caffeine, nicotine or over the counter cold medicines within 12 hours of the cardiac PET-MRI examination
* Use of the medication dipyridamole within 48 hrs of the cardiac PET-MRI examination
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01779869
Study Brief:
Protocol Section:
NCT01779869